The use of allogeneic "universal donor" mesenchymal stromal cells (MSCs) may be a substantial clinical convenience for treatment of autoimmune ailments such as multiple sclerosis. We therefore tested whether allogeneic MSCs can be exploited for treatment of experimental autoimmune encephalomyelitis (EAE) in mice with otherwise intact immune system. Administration of allogeneic Balb/c-derived MSCs to C57Bl/6 mice with pre-established EAE led to a significant decrease in disease score over time comparable to that achieved with syngeneic MSCs, and was correlated with a significant blunting of immune cell infiltration to the spinal cord and reduced circulating levels of interferon-γ (IFN-γ) and interleukin-17. Pretreatment of allogeneic MSCs with IFN-γ increased the expression levels of CCL2 as well as major histocompatibility complex I (MHCI) and MHCII, but also led to complete loss of suppressive activity in vivo that correlated with immune rejection. In conclusion, allogeneic MSCs can suppress the manifestations of EAE, yet retain the potential for alloimmunization.
IntroductIon
Mesenchymal stromal cells (MSCs) possess clinical potential for the treatment of many ailments, [1] [2] [3] [4] [5] [6] and are the object of numerous early phase human clinical trials. One of the most remarkable and perhaps least understood ability of MSCs is their immunomodulatory capacity. More specifically, MSCs have been shown to prolong skin allograft survival in baboons, 7 prevent the rejection of allogeneic tumor cells in immunocompetent mice 8 in addition to their capacity to alleviate murine experimental autoimmune encephalomyelitis (EAE) 9 and steroid-resistant graft-versus-host disease in humans. 10 We have recently demonstrated that syngeneic MSCs can inhibit plasma cells 11 in vitro and in vivo and lead to therapeutic improvement in EAE mice 12 via extracellular conversion of CCL2 to an antagonist N-terminus cleaved form by matrix metalloproteinase processing. 13 Therefore, MSCs possess the ability to proteolytically modify their extracellular chemokine milieu-CCL2 in particular-in a manner leading to suppression of Th1-, Th2-, and Th17-driven autoimmune responses. Though MSCs are immune suppressive, they are not necessarily immune privileged when administered to immune-competent allorecipients 14 and may even break tolerance to autoantigens. 15 However, the sheer convenience of mass-produced "universal donor" MSCs to treat human ailments-in contrast to a customized, patient-specific cell product -begets testing despite the theoretical risks associated with loss of function arising from alloimmunization. Therefore, we tested whether major histocompatibility complex (MHC)-mismatched MSCs can improve the outcome of symptomatic EAE. We find that both syngeneic and allogeneic MSCs can partially and equally improve EAE disease score and neuropathology, but only allogeneic cells have the potential for alloimmunization.
results

Msc preparation and characterization
MSCs from either C57Bl/6 (Figure 1a) or Balb/c mice had similar phenotypes characterized by the expression of CD44, CD73, and CD105 whereas being negative for CD45. Their expansion in vitro did not alter their capacity to differentiate into adipocytes and osteoblasts confirming therefore that the expanded cells are of MSC origin (Figure 1b) .
Msc-derived ccl2 and Mlr
The presence of CCL2 in the conditioned media (CM) of both C57Bl/6 and Balb/c MSCs was confirmed by enzyme-linked immunosorbent assay (ELISA) and shown to be significantly enhanced by interferon-γ (IFN-γ) treatment in vitro (Figure 2a) . A noticeable upregulation of both MHCI and MHCII were detected by flow cytometry following the addition of IFN-γ (Figure 2b ). We further demonstrate that MSC CM is capable of blocking a two-way mixed lymphocyte reaction (MLR) in a CCL2 dosedependent manner (Figure 3a) . The addition of CCL2 neutralizing antibody to the MLR completely abolished the observed suppression demonstrating the direct involvement of MSC-derived CCL2 inhibiting lymphocyte activation and their production of IFN-γ (Figure 3b) , as previously reported.
12
Msc injection in eAe mice and hematological analysis Once delivered in vivo, both syngeneic and allogeneic MSC populations were capable in reducing EAE severity by almost 50% over 2 months (Figure 4a) . Interestingly, pretreatment of allogeneic MSCs with IFN-γ was accompanied by a complete loss of effect on EAE disease score (Figure 4b, lower pro-inflammatory cytokines IFN-γ and interleukin-17 in EAE mice treated with both syngeneic and allogeneic MSCs decreased significantly, whereas mice treated with IFN-γ-activated allogeneic MSCs had plasma interleukin-17 and IFN-γ levels indistinguishable from untreated EAE mice (Figure 5a ). This observation was further confirmed by the in vitro restimulation of splenocytes with MSCs demonstrating acquired alloimmunization (Figure 5b ). To demonstrate the direct involvement of CCL2 in IFN-γ inhibition, the addition of CCL2 neutralizing antibody (2.5 µg/ml) to the MLR reaction has reversed the IFN-γ inhibition effect to a comparable level with the positive control (n = 5 and *P < 0.00002). CM, conditioned media; IFN-γ, interferon-γ; MSC, mesenchymal stromal cell; n.d., not detected; NS, not significant. the total number of CD4 T cells only in mice treated with resting allogeneic MSCs (Figure 6b) .
Analysis of spinal cord immune infiltrates
dIscussIon
Syngeneic MSCs have been shown to be effective in reducing neuroinflammation in EAE mice, 9, 11 and this effect is mediated by MSC production of matrix metalloproteinase-processed derivative of CCL2 (ref. 12). The translation of this MSC-based therapeutic strategy to the clinic would entail the manufacturing of a patient-specific custom cellular pharmaceutical, a time-consuming and potentially onerous process that might not be optimal for widespread use in actively ill patients. Batch-produced universal donor allogeneic MSCs would be available without delay-a substantial advantage for acutely ill subjects. However, MSCs have been shown to be susceptible to immune rejection when administered to adult MHCmismatched recipients with intact immune systems. 14, 15 Would administration of allogeneic MSCs attenuate the encephalitogenic manifestations of EAE in the window of time before their penultimate clearance in vivo? To answer this question, we compared the therapeutic efficacy of MHC-matched or -mismatched MSCs in alleviating EAE. It has been recently found that in vivo suppressive effect of MSCs is dependent, in part, upon their expression of the IFN-γ receptor. 16 The notion being, that upon IFN-γ stimulation, MSC produces nitric oxide and undisclosed chemokines. 16 Consistent with this model, we found that in vitro stimulation of MSCs led to a substantial increase in production of CCL2 but was also accompanied by upregulation of MHCI and MHCII as well as we and others have previously described. [17] [18] [19] Interestingly, pretreatment of allogeneic MSCs with IFN-γ was accompanied by a complete loss of effect on EAE disease score. This loss of immunosuppressive property could be explained by the upregulation of MHCI and MHCII molecules and subsequent rejection by the recipient's immune system as previously described.
14,15 Although EAE mice treated with "resting" allogeneic MSCs saw their levels of circulating pro-inflammatory cytokines and spinal cord immune infiltrates decrease significantly, those treated with IFN-γ-activated allogeneic MSCs did not lead to a distinguishable response when compared to untreated EAE mice.
In conclusion, "resting" allogeneic MSCs are as effective as their syngeneic counterparts in partially attenuating the manifestations of pre-established EAE. Though it has been proposed that MSC suppressive effect depends, in part, on IFN-γ-mediated activation in vivo, we find that performing IFN-γ priming of allogeneic MSCs in vitro prior to their administration to EAE mice did not enhance their therapeutic utility. To the contrary, IFN-γ-primed allogeneic MSCs completely lost their suppressive effects in vivo and was associated with an enhanced alloimmune response directed against the MHC-mismatched cells suggesting that an accelerated immune clearance of cells may be the root cause of their loss of effect. These data suggest that allogeneic MSCs may be of use for treatment of EAE, but their effectiveness may be hampered by acquired alloimmune response, especially if they are IFN-γ-activated.
MAterIAls And Methods
Reagents. All mice were purchased from the Jackson Laboratory (Bar Harbor, ME). ELISAs, CCL2 neutralizing antibody, isotype antibody, and IFN-γ were purchased from R&D Systems (Minneapolis, MN). FACS antibodies for CD44, CD45, CD73, CD105, MHCI, and MHCII were purchased from BD Biosciences (San Diego, CA).
MSC preparation. Bone marrow from femurs and tibiae of mice was harvested and placed in culture as reported previously 14 and their phenotype analyzed by flow cytometry. MSCs were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 50 ng/ml of gentamicin up to 80% confluency before their use in vitro or in vivo. For differentiation, MSCs were cultured in osteogenic or adipogenic media and analyzed as previously described.
11 MSC versus NIH-3T3 CM was used to quantify CCL2 levels before and after IFN-γ stimulation (2 ng/ ml) by ELISA. To verify whether IFN-γ activated MSCs, a flow cytometric analysis of MHCI and MHCII was conducted.
MLR and CCL2 neutralization experiments.
To test the immunosuppressive property of syngeneic and allogeneic MSC CM, 80% confluent C57Bl/6 (syngeneic) or Balb/c (allogeneic) MSCs were cultured for 24 hours in serumfree Dulbecco's modified Eagle's medium and the CM concentrated 100× using Centricons. A twofold serial dilution of CM was added to a two-way MLR using C57Bl/6 and Balb/c splenocytes (10 5 cells of each). The cells were left for 72 hours in splenocyte media (RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mmol/l l-glutamine, 0.01 mol/l 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, 1 mmol/l sodium pyruvate, 50 µmol/l β-mercaptoethanol, and 50 ng/ml of gentamicin) containing the diluted MSC CM (1/3 of the entire volume) in 96-well plates. The supernatants were then collected and tested by ELISA for IFN-γ. For CCL2 neutralization experiments, a similar MLR was conducted as previously explained. Briefly, 10 5 C57Bl/6 and Balb/c splenocytes were cocultured in the presence of 2.5 µg/ml of isotype or CCL2 neutralizing antibody for 72 hours. The media was then collected and screened for IFN-γ production by ELISA. EAE induction and MSC administration. EAE was induced in mice (n = 10 per condition) as previously reported. 20 Following the appearance of EAE symptoms, mice were scored, stratified, and assigned to separate test groups in order to obtain equally weighted average disease scores prior to experimental interventions. Every mouse received an intraperitoneal administration of 2 × 10 6 MSCs versus phosphate-buffered saline. Allogeneic MSCs were administered in "resting state" or following stimulation with 2 ng/ml of IFN-γ 24 hours prior to injection.
Immune and histological analysis. Blood samples were obtained from mice 1 month following MSC treatment to analyze circulating levels of IFN-γ and interleukin-17 by ELISA. To analyze the cellular response, 2 × 10 6 resting or IFN-γ-stimulated Balb/c MSCs were injected in EAE mice, and 32 days later, splenocytes were harvested and restimulated with Balb/c MSCs in vitro. The CM was removed 72 hours later and tested by ELISA for IFN-γ secretion. For histology purposes, EAE mice were perfused with 20 ml phosphate-buffered saline before the removal of their spinal cord. Sections were then stained with hematoxylin and eosin. For flow cytometric analysis of CD4 T cells, spinal cords were mechanically disrupted to generate single cell suspension and analyzed by FACSCalibur cytometer (BD Biosciences). The background generated by cell debris was subtracted from the positive staining of CD4 T cells using naive, nontreated, C57Bl/6 mice spinal cords.
Statistical analysis. P values were calculated by paired Student's t-test. 
